COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.

ABSTRACT:

Background/aims

Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody.

Methods

We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses.

Results

Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76-90%) and 91% (95% CI, 83-95%), based predominantly on neutralizi

SUBMITTER: Cheung KS 

PROVIDER: S-EPMC9597217 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature